2. Search Result
Search Result
Results for "

morphinan

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N1356A
    (R)-Reticuline

    		Cytochrome P450 Inflammation/Immunology
    (R)-Reticuline is a key intermediate and precursor in the biosynthetic pathway of morphinan alkaloids. (R)-Reticuline plays a central role in the metabolism of opium poppy (Papaver somniferum). (R)-Reticuline can either undergo O-methylation catalyzed by PSOMT1, or be converted to (+)-Salutaridine via regioselective and stereoselective oxidative coupling under the action of salutaridine synthase (CYP719B1). (R)-Reticuline serves as a direct precursor for the synthesis of important alkaloids such as morphine, codeine and thebaine .
    (R)-Reticuline
  • HY-W856819
    Eseroline

    		Opioid Receptor Cholinesterase (ChE) Drug Metabolite nAChR Neurological Disease
    Eseroline is a potent μ-opioid receptor agonist, which is the hydrolytic metabolite of Physostigmine (HY-N6608). Eseroline is a selective and competitive acetylcholinesterase (AChE) inhibitor, with its Ki values for AChE and BuChE being 0.1 μM and 200 μM respectively. Eseroline has nicotinic acetylcholine receptor allosteric enhancing ligand (nAChR-APL) activity, meaning it does not activate the receptor but significantly enhances the signal transduction of Ach triggered by the receptor. Eseroline is neurotoxic, causing cell membrane damage (LDH leakage) and energy metabolism collapse (ATP depletion). Eseroline can be used for the study of Alzheimer's disease .
    Eseroline
  • HY-159923
    BPRMU191

    		Opioid Receptor Neurological Disease
    BPRMU191 is a μ-opioid receptor (MOR) modulator that converts small-molecule morphinan antagonists into G protein-biased MOR agonists, thereby inducing MOR-dependent activation and analgesic effects. Co-administration of BPRMU191 with morphinan antagonists provides analgesia while reducing side effects such as gastrointestinal dysfunction, antinociceptive tolerance, and dependency-related adverse effects. BPRMU191, in combination with morphinan antagonists, offers a potential strategy for studying severe pain management and G protein-coupled receptor modulation .
    BPRMU191
  • HY-177790
    Orexin receptor antagonist 7

    		Orexin Receptor (OX Receptor) Neurological Disease
    Orexin receptor antagonist 7 (Compound 34) is an antagonist of the orexin receptor (OX1R), with a Ki value of 4.05 nM. Orexin receptor antagonist 7 shows no detectable activity towards OX2R and has very low affinities for the three opioid receptors (μ, δ, κ) (Ki > 1,000 nM). Orexin receptor antagonist 7 can be used for research on opioid addiction .
    Orexin receptor antagonist 7
  • HY-E71139
    1,2-Dehydroreticulinium reductase (NADPH)

    		Biochemical Assay Reagents Others
    1,2-Dehydroreticulinium reductase (NADPH) (EC 1.5.1.27) reduces the 1,2-Dehydroreticulinium ion to (R)-reticuline, which is a direct precursor of morphinan alkaloids in the poppy plant.
    1,2-Dehydroreticulinium reductase (NADPH)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: